QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development.
暂无分享,去创建一个
[1] Vincent Gm,et al. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. , 1998 .
[2] J. Lynch,et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.
[3] A Varró,et al. Delayed rectifier potassium current in undiseased human ventricular myocytes. , 1998, Cardiovascular research.
[4] L. Furness,et al. Pharmacogenomics - it's not just pharmacogenetics. , 1998, Current opinion in biotechnology.
[5] S Nattel,et al. Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. , 1999, Circulation research.
[6] T. Stern,et al. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. , 1995, Psychosomatics.
[7] W. Crumb,et al. Description of a nonselective cation current in human atrium. , 1995, Circulation research.
[8] J. Towbin,et al. Molecular genetics of long QT syndrome from genes to patients. , 1997, Current opinion in cardiology.
[9] T. Yamamoto,et al. Blockage by terfenadine of the adenosine triphosphate (ATP)-sensitive K+ current in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.
[10] J J Heger,et al. Sudden cardiac death. , 1998, Circulation.
[11] S. Priori. Exploring the Hidden Danger of Noncardiac Drugs , 1998, Journal of cardiovascular electrophysiology.
[12] C T Dollery. Drug discovery and development in the molecular era. , 1999, British journal of clinical pharmacology.
[13] D. Roden,et al. Torsade de pointes , 1993, Clinical cardiology.
[14] D. Mckinnon,et al. Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats. , 1994, Circulation research.
[15] S. Nattel,et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. , 1997, Circulation research.
[16] H. Refsum,et al. Rate‐Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK‐68,798: Potent in Guinea Pig but no Effect in Rat Myocardium , 1990, Journal of cardiovascular pharmacology.
[17] J A Kors,et al. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. , 1999, European heart journal.
[18] Y. Ukai,et al. Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs. , 1998, General pharmacology.
[19] D. Snyders,et al. Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. , 1997, Cardiovascular research.
[20] M. Keating,et al. The long QT syndrome. A review of recent molecular genetic and physiologic discoveries. , 1996, Medicine.
[21] D. Zipes,et al. In Vivo and In Vitro Electrophysiologic Effects of Terodiline on Dog Myocardium , 1995, Journal of cardiovascular electrophysiology.
[22] D. Mckinnon,et al. Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. , 1996, Circulation research.
[23] R. Gilmour,et al. Decreased Density of Ito in Left Ventricular Myocytes from German Shepherd Dogs with Inherited Arrhythmias , 1997, Journal of cardiovascular electrophysiology.
[24] A. Brown,et al. Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.
[25] M. Morad,et al. Comparative effects of loratadine and terfenadine on cardiac K+ channels. , 1997, Journal of cardiovascular pharmacology.
[26] D. Roden,et al. Cisapride‐Induced Torsades de Pointes , 1998, Journal of cardiovascular electrophysiology.
[27] A. Brown,et al. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.
[28] H. Just,et al. Drug-Induced Torsade de Pointes , 1994, Drug safety.
[29] J. Camm,et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. , 1998, European heart journal.
[30] P E Puddu,et al. The shape of human atrial action potential accounts for different frequency-related changes in vitro. , 1996, International journal of cardiology.